[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T, Tsuchiya H, Beppu Y, Morioka H, Yabe H, Japanese Musculoskeletal Oncology Group: Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer; 2007 Jan 1;109(1):109-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Clear cell sarcoma (CCS) of tendons and aponeuroses (malignant melanoma of soft parts) is a rare melanocytic soft tissue sarcoma.
  • The objective of this study was to determine the clinical features, prognostic factors, and optimal treatment policy for patients with this rare disease.
  • METHODS: Seventy-five consecutive patients with histologically confirmed CCS who received treatment between 1980 and 2004 were analyzed retrospectively.
  • Sixty-five tumors were located in the extremities, and 10 tumors were located in the trunk.
  • Seventy-one patients underwent surgical excision, and 56 patients received chemotherapy.
  • Sixteen patients developed local recurrences, and 52 patients developed metastasis.
  • Among the 52 patients who presented with localized disease, sex (P = .023), tumor size (P = .002), tumor depth (P = .011), TNM classification (P = .004), and chemotherapy (P = .032) were identified as significant prognostic factors.
  • CONCLUSIONS: The current results supported the contention that early diagnosis and initial wide excision are essential for a favorable outcome of CCS.
  • The role of chemotherapy for CCS should be investigated further.
  • [MeSH-major] Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / therapy. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / therapy. Tendons
  • [MeSH-minor] Adult. Female. Humans. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / therapy. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17133413.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Fu DL, Yang F, Maskay A, Long J, Jin C, Yu XJ, Xu J, Zhou ZW, Ni QX: Primary intestinal malignant fibrous histiocytoma: two case reports. World J Gastroenterol; 2007 Feb 28;13(8):1299-302
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal malignant fibrous histiocytoma: two case reports.
  • Malignant fibrous histiocytoma (MFH) occurs most commonly in the extremities and trunk, but rarely in the intestine.
  • They were not treated with chemotherapy or radiotherapy and both died within 3 mo.
  • MFH of the intestine is an extremely rare neoplasm with an aggressive biological behavior.
  • Complete surgical excision is preferred, adjuvant chemotherapy or radiotherapy may be advisable.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Intestinal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Burns. 2000 May;26(3):305-10 [10741601.001]
  • [Cites] Surg Today. 2005;35(4):323-7 [15815852.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Skeletal Radiol. 2003 Nov;32(11):613-8 [14517697.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1156-60 [15387338.001]
  • [Cites] Burns. 2004 Nov;30(7):742-5 [15475153.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):554-63 [7690726.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):91-6 [8548744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):718-24 [9361108.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 15;100(2):134-42 [9428357.001]
  • [Cites] Surg Today. 1999;29(2):160-4 [10030742.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):447-8 [10419723.001]
  • [Cites] APMIS. 1999 Sep;107(9):837-42 [10519319.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Surg Today. 2001;31(3):242-5 [11318129.001]
  • (PMID = 17451221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147015
  •  go-up   go-down


3. Weisskopf M, Münker R, Hermanns-Sachweh B, Ohnsorge JA, Siebert C: Epithelioid sarcoma in the thoracic spine. Eur Spine J; 2006 Oct;15 Suppl 5:604-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid sarcoma is a rare and highly malignant soft tissue tumor that is commonly found in the extremities and rarely in the trunk area.
  • This malignant tumor often mimics granuloma or nodular fasciitis, which causes a delay in establishing the diagnosis.
  • This type of cancer has a high recurrence rate.
  • Surgical treatment requires wide radical resection.
  • The objective of this case report is to highlight the unique location of a rare neoplasm and to illustrate the relentless course of epithelioid sarcoma despite initial radical resection.
  • A 14-year-old boy was admitted to our facility with a soft tissue mass on the right lower thoracic spine.
  • The patient received chemotherapy and irradiation.
  • The first recurrence of the neoplasm was seen as a contralateral metastasis 21 months after the resection.
  • Initial wide excision of the neoplasm and adjuvant therapy including chemotherapy and irradiation seem to slow down the relentless course of epithelioid sarcoma in the trunk.
  • [MeSH-major] Orthopedic Procedures. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Spinal Neoplasms / diagnosis. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Biopsy. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Orthopedic Fixation Devices. Positron-Emission Tomography. Postoperative Period. Radiography, Thoracic. Spinal Fusion

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 2002;26(1):26-30 [11954844.001]
  • [Cites] Radiology. 2004 Mar;230(3):697-702 [14749514.001]
  • [Cites] Cancer. 1970 Nov;26(5):1029-41 [5476785.001]
  • [Cites] Pol Med J. 1971;10(1):12-7 [5573897.001]
  • [Cites] Cancer. 1972 Jul;30(1):128-43 [4339255.001]
  • [Cites] Cancer. 1972 Aug;30(2):486-99 [4340662.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):491-5 [9309338.001]
  • [Cites] Cancer. 1978 Apr;41(4):1472-87 [639005.001]
  • [Cites] Am J Surg Pathol. 1985 Apr;9(4):241-63 [4014539.001]
  • [Cites] J Bone Joint Surg Am. 1988 Jul;70(6):862-70 [3392084.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):345-9 [2759252.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1189-91 [7807342.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Mar 1;21(5):634-8 [8852321.001]
  • [Cites] Cancer. 1977 Jan;39(1):143-52 [188535.001]
  • (PMID = 16474944.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC1602205
  •  go-up   go-down


Advertisement
4. Gerstein J, Kofahl-Krause D, Frühauf J, Bremer M: Complete remission of a lymphoma-associated chylothorax by radiotherapy of the celiac trunk and thoracic duct. Strahlenther Onkol; 2008 Sep;184(9):484-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a lymphoma-associated chylothorax by radiotherapy of the celiac trunk and thoracic duct.
  • BACKGROUND: A chylothorax is a rare complication of mostly advanced malignant lymphomas.
  • A case of a refractory chylothorax unresponsive to chemotherapy and successfully treated with radiotherapy is reported.
  • The CT scans showed bulky lymphadenopathy at the thoracic trunk but no detectable enlargement of mediastinal lymph nodes.
  • After ineffective pretreatment including chemotherapy and chest drainage, fractionated radiotherapy to the celiac trunk (20.4 Gy) and the thoracic duct (15 Gy) was performed.
  • RESULT: Already after 7.5 Gy a rapid decline of chylothorax was noted and the chest drain could be removed.
  • A complete remission of the chylothorax could be achieved after 20.4 Gy.
  • CT scans showed nearly complete remission of the lymphadenopathy of the celiac trunk 12 months after radiotherapy.
  • CONCLUSION: Radiotherapy with limited total doses is an effective treatment option for lymphoma-associated chylothorax and should always be taken into consideration, especially in cases unresponsive to chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Lymphatic Irradiation. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016028.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Engellau J, Samuelsson V, Anderson H, Bjerkehagen B, Rissler P, Sundby-Hall K, Rydholm A: Identification of low-risk tumours in histological high-grade soft tissue sarcomas. Eur J Cancer; 2007 Sep;43(13):1927-34
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of low-risk tumours in histological high-grade soft tissue sarcomas.
  • In more than one-third of patients with a histological high-grade malignant soft tissue sarcoma metastasis develops despite local control of the primary tumour.
  • Hence, adjuvant chemotherapy is increasingly used for these relatively chemoresistant tumours which requires improved prognostication to exclude low-risk patients from overtreatment.
  • We assessed the value of stepwise prognostication in a series of 434 histological high-grade STS of the extremity and trunk wall.
  • This model improved prognostication in STS and is of value for identifying patients who probably should not receive adjuvant chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / prevention & control. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627813.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Stark AM, Buhl R, Hugo HH, Mehdorn HM: Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien); 2001;143(4):357-63; discussion 363-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature.
  • BACKGROUND: Though Malignant peripheral nerve sheath tumours (MPNST) are a rare entity accounting for 5-10% of soft-tissue sarcomas they are an important differential diagnosis to benign tumours of the peripheral nervous system regarding treatment and prognosis.
  • Two patients suffered from Neurofibromatosis type 1.
  • Four tumours were localised at the head & neck region, three were found in the extremities and one tumour was located on the trunk.
  • All patients underwent surgery with curative intent, but total resection, defined by negative surgical margins, was achieved in only 3 cases.
  • All of these developed local recurrence with a mean disease free survival time of 10.6 months.
  • During follow up, three patients developed distant metastases located in the lung, liver and subcutaneous tissue.
  • Five out of eight patients died during follow-up with a mean survival time of 11.6 months after diagnosis.
  • INTERPRETATION: MPNST is a rare and fatal diagnosis in neurosurgery with high risk of local recurrence and occurence of distant metastases.
  • Though mulitimodal therapy including surgical resection and adjuvant radiotherapy including brachytherapy is available, the prognosis remains dismal.
  • Modern clinical studies and the development of effective chemotherapy is needed in order to gain control of the disease.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / surgery. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / surgery. Thoracic Neoplasms / mortality. Thoracic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437289.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 5
  •  go-up   go-down


7. Thijssens K, Vaneerdeweg W, Schrijvers D, Eyskens E, Van Oosterom A: Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer. Acta Chir Belg; 2003 Nov-Dec;103(6):599-602
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
  • OBJECTIVE: To assess the results of retroperitoneal lymph node dissection (RPLND) of residual masses in patients with disseminated non-seminomatous germ cell tumour treated with cisplatin-based chemotherapy, both in terms of extension of surgery, morbidity and survival.
  • In patients with non-seminomatous testicular cancer more than stage I, the 'wait and see' strategy changed and patients were treated with chemotherapy.
  • Patients were assessed at the end of chemotherapy and if a residual masses persisted, a RPLND was performed.
  • Forty-seven patients were treated with cisplatin-based chemotherapy.
  • Fifteen patients underwent RPLND above the level of the renal trunk.
  • In two patients malignant cells or fibrotic tissue were found above the renal trunk and bilateral.
  • In five patients viable tumour cells were found in the region below the renal trunk.
  • Sixteen patients underwent RPLND below the level of the renal trunk, of which nine had a unilateral resection, containing viable tumour in two patients.
  • CONCLUSION: RPLND has a place in the treatment of patients with non-seminomatous testicular cancer after chemotherapy in case of residual masses.
  • In a limited number of patients there was a need of resection of adherent organs when a resection above the renal trunk was performed.
  • [MeSH-minor] Adult. Belgium. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743567.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


8. Wang JR, Yu KJ, Juan WH, Yang CH: Metastatic malignant melanoma associated with vitiligo-like depigmentation. Clin Exp Dermatol; 2009 Mar;34(2):209-11
MedlinePlus Health Information. consumer health - Vitiligo.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic malignant melanoma associated with vitiligo-like depigmentation.
  • Vitiligo-like depigmentation in patients with malignant melanoma is a poorly understood phenomenon.
  • We report a patient who presented with a 4-month history of vitiligo-like depigmentation of the face, trunk and limbs.
  • A needle biopsy taken from the lymph nodes revealed metastatic malignant melanoma.
  • The patient died from sepsis, the main complication of immunosuppressive therapy, without evidence of distant metastasis.
  • We also propose that, due to the favourable prognosis in patients with malignant melanomas and vitiligo-like depigmentation, the treatment plan may be more conservative to minimize the adverse effects of chemotherapy.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2015 Jun;40(4):453-5 [25438833.001]
  • (PMID = 18691245.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Shah BK, Qamruzzaman Y, Serban K, Hire E, Ying SC: First case report of locally advanced malignant nodular hidradenoma of the scrotum. Onkologie; 2010;33(12):701-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First case report of locally advanced malignant nodular hidradenoma of the scrotum.
  • BACKGROUND: Malignant nodular hidradenoma (MNH) is a malignant tumor of the eccrine glands, and most commonly involves the head, trunk, and extremities.
  • Despite the use of surgery, chemotherapy, radiotherapy, and hormonal therapy, optimal treatment of MNH is unclear.
  • Surgery alone may be sufficient for the treatment of localized or locally advanced MNH.
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21124043.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Govier SM: Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract; 2003 May;18(2):103-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of treatment for mast cell tumors.
  • Mast cell tumors (MCT) are the most common malignant cutaneous tumors that occur in dogs.
  • They are most commonly found on the trunk, accounting for approximately 50% to 60% of all sites.
  • The extent of staging procedures following fine-needle aspirate cytologic diagnosis is based on the presence or absence of negative prognostic indicators.
  • Surgery is the treatment of choice for solitary MCTs with no evidence of metastasis.
  • Reponses rates to chemotherapy, (partial response) as high as 78% have been reported, and preliminary evidence suggests that multiagent (prednisone and vinblastine) protocols may confer a higher response rate than single-agent therapy.
  • Unlike in the dog, the head and neck are the most common sites for MCTs in the cat followed by the trunk and limbs.
  • The diagnosis and staging of MCTs in cats is similar to that in the dog.
  • As with dogs with cutaneous MCTs, surgery is the treatment of choice.
  • Little is known about the effectiveness of adjunctive chemotherapy options for cutaneous MCTs.
  • Adjunctive chemotherapy does not appear to increase survival times.
  • [MeSH-major] Cat Diseases / diagnosis. Dog Diseases / diagnosis. Mast-Cell Sarcoma / veterinary
  • [MeSH-minor] Animals. Cats. Dogs. Neoplasm Staging / veterinary. Prognosis. Veterinary Medicine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12831070.001).
  • [ISSN] 1096-2867
  • [Journal-full-title] Clinical techniques in small animal practice
  • [ISO-abbreviation] Clin Tech Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


11. Belmadani K, Amahzoune B, Selkane C, Boulahya A, el Fakir Y, al Bouzidi A, el Kirat A: [Invasive thymoma extending into the superior vena cava and the right atrium: a case report and review of the literature]. Ann Cardiol Angeiol (Paris); 2001 Jun;50(4):217-23
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Thymome invasif à extension intra-cave supérieure et intra-atriale droite: à propos d'un cas et revue de la littérature.
  • The transthoracic echocardiography supplemented by the echocardiography transoesophageal pose the cardiac diagnosis of tumor, and it is the thoracic tomodensitometry which highlights a tumoral process mediastinal of malignant pace invading the left inominal venous trunk, the higher vena cava and extending in the right auricle.
  • The diagnosis of certainty is carried by the endobronchial biopsy and the puncture tomodensitometric biopsy under control of the mediastinal mass after anatomopathological examination.
  • Under chemotherapy, the evolution over 18 months is marked by the absence of cardiovascular complications in spite of the non regression of the tumoral mass.
  • The surgery when it is possible, remains the principal therapeutic measurement which really proved reliable.
  • [MeSH-major] Heart Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Thymoma / diagnosis. Thymus Neoplasms / diagnosis. Vascular Neoplasms / diagnosis. Vena Cava, Superior
  • [MeSH-minor] Aged. Heart Atria. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12555596.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Akhtar S, Oza KK, Wright J: Merkel cell carcinoma: report of 10 cases and review of the literature. J Am Acad Dermatol; 2000 Nov;43(5 Pt 1):755-67
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of the limitation of retrospective data, optimal treatment is not well defined.
  • OBJECTIVE: Our purpose was to present the clinical course and treatment of 10 patients with MCC and review the published literature on MCC.
  • The medical literature was also reviewed for natural history and treatment recommendations using MEDLINE search.
  • RESULTS: Five men and 5 women received their treatment between 1986 and 1998 for MCC (5 had stage IA disease, 4 stage IB, 1 stage II).
  • Five of 10 patients had a relapse (mean time before recurrence, 5.7 months) (range, 2 weeks-20 months); one patient had local recurrence, one had regional lymph node recurrence, and 3 had both local and regional lymph node recurrence.
  • In 4 patients systemic metastases developed.
  • After initial surgery, 9 patients received radiotherapy at some point and 3 patients also received chemotherapy.
  • Five of 10 patients had 13 previously treated or coexisting malignant neoplasms.
  • In one patient MCC developed in a previously irradiated field.
  • Review of 875 cases showed a male/female ratio of 1.5:1; location of tumors was as follows: head and neck, 47%; extremities, 40%; trunk, 8%; unknown primary site, 5%.
  • The role of chemotherapy is still controversial and should be considered in patients with advanced disease and those not thought to be candidates for surgery.
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11050578.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


13. Scoggins CR, Pisters PW: Diagnosis and management of soft tissue sarcomas. Adv Surg; 2008;42:219-28
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of soft tissue sarcomas.
  • STS are a heterogeneous group of malignant tumors that pose significant management challenges.
  • The cornerstone of therapy for patients who have primary STS remains margin-negative resection.
  • Adjuvant radiotherapy has been shown to reduce the risk of recurrence for extremity and trunk STS, although its role for retroperitoneal STS remains to be defined.
  • Chemotherapy is usually reserved for chemotherapy-sensitive histologic subtypes and for patients who have metastatic STS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953820.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


14. Farley J, O'Boyle JD, Heaton J, Remmenga S: Extraosseous Ewing sarcoma of the vagina. Obstet Gynecol; 2000 Nov;96(5 Pt 2):832-4
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ewing sarcoma is a highly malignant childhood bone neoplasm.
  • Extraosseous presentations of Ewing sarcomas include the trunk, extremities, uterus, cervix, and vagina.
  • Chemotherapy was given, followed by external beam and vaginal intracavitary brachytherapy, then more chemotherapy.
  • After 48 months post-treatment, there is no clinical evidence of recurrence.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094227.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Pakos EE, Gogou PV, Apostolikas N, Batistatou A, Tsekeris PG: Factors associated with outcome in liposarcomas of the extremities and trunk. J BUON; 2010 Jul-Sep;15(3):518-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with outcome in liposarcomas of the extremities and trunk.
  • PURPOSE: Liposarcomas are malignant tumors that arise from primitive mesenchymal cells rather than mature adipose tissue.
  • We aimed to evaluate the outcomes of patients with extremities and superficial trunk liposarcomas in relation to some clinicopathological factors.
  • In univariate analysis factors that were significantly associated with outcomes were grade III tumors, amputation procedures, use of chemotherapy and development of local recurrences.
  • The development of metastases is observed within the first 5-years from diagnosis.
  • [MeSH-major] Liposarcoma / mortality. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Extremities. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941821.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


16. Suehara Y, Yazawa Y, Hitachi K, Terakado A: Clear cell sarcoma arising from the chest wall: a case report. J Orthop Sci; 2004;9(2):171-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell sarcoma is a rare malignant soft tissue neoplasm that usually arises adjacent to tendons or aponeuroses.
  • The principal sites of this neoplasm are the extremities, but tumors do occur in the trunk on rare occasions.
  • A diagnosis of clear cell sarcoma was confirmed.
  • She was treated with two courses of chemotherapy using ifosfamide, carboplatin, and etoposide.
  • Subsequently, the tumor, including adjacent tissue, the chest wall, and sternum, was resected with a wide margin; and the defect of the chest wall was covered with Marlex mesh fabric, regin, and a musculocutaneous flap.
  • [MeSH-major] Sarcoma, Clear Cell / diagnosis. Soft Tissue Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis. Thoracic Wall

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045547.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Murakami T, Ohtsuki M, Nakagawa H: Angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma with cutaneous infiltration: report of a case and its gene expression profile. Br J Dermatol; 2001 Apr;144(4):878-84
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma with cutaneous infiltration: report of a case and its gene expression profile.
  • Angioimmunoblastic T-cell lymphoma is a type of peripheral T-cell lymphoma that is clinically characterized by high fever and generalized lymphadenopathy with or without cutaneous involvement.
  • A 55-year-old Japanese man presented with red papular lesions on the trunk and limbs, oedema, and generalized lymphadenopathy.
  • Based on these findings, a diagnosis of angioimmunoblastic T-cell lymphoma with cutaneous infiltration was made.
  • Despite systemic chemotherapy, the disease exhibited a high level of activity and continued on a fatal course.
  • An analysis of gene expression profiling using complementary DNA microarrays revealed significant expression of some chemokines and cytokines, e.g. secondary lymphoid tissue chemokine, macrophage inflammatory protein (MIP)-1beta, MIP-3alpha, MIP-3beta, B-lymphocyte chemokine, interleukin-16 and tumour necrosis factor-beta, and an apoptosis-inhibitory protein (FLICE inhibitory protein) in the affected lymph nodes.
  • Profiling of gene expression patterns for a variety of genes in additional cases may be helpful in determining which factors predict the biological and clinical behaviour of angioimmunoblastic T-cell lymphoma or other aggressive malignant lymphomas.
  • [MeSH-minor] Cytokines / genetics. Cytokines / metabolism. Fatal Outcome. Gene Expression. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298554.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


18. McGrory JE, Pritchard DJ, Arndt CA, Nascimento AG, Remstein ED, Rowland CM: Nonrhabdomyosarcoma soft tissue sarcomas in children. The Mayo Clinic experience. Clin Orthop Relat Res; 2000 May;(374):247-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonrhabdomyosarcoma soft tissue sarcomas in children. The Mayo Clinic experience.
  • Eighty-six children to 18 years of age were treated for nonrhabdomyosarcoma soft tissue sarcomas of the trunk and extremities.
  • Synovial sarcoma (31), fibrosarcoma (13), malignant fibrous histiocytoma (11), epithelioid sarcoma (10), and clear cell sarcoma (7) were the most common diagnoses.
  • Patients were treated with wide removal of the tumor when possible, with judicious use of adjuvant radiation, or with chemotherapy in selected cases.
  • When compared with published data in adults, the prognosis of primary, localized nonrhabdomyosarcoma soft tissue sarcomas in children appears to be more favorable.
  • [MeSH-major] Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Sarcoma / pathology. Sarcoma / surgery. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery. Sarcoma, Synovial / pathology. Sarcoma, Synovial / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Age Factors. Biopsy. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10818984.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Petković M, Zamolo G, Muhvić D, Coklo M, Stifter S, Antulov R: The first report of extraosseous Ewing's sarcoma in the rectovaginal septum. Tumori; 2002 Jul-Aug;88(4):345-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing's sarcoma is a highly malignant neoplasm of bone, which usually occurs during childhood.
  • Common extraosseous localizations of Ewing's sarcoma include the trunk, extremities, uterus, cervix and vagina.
  • The mass had a size of 9 x 6 cm, a soft tissue consistency, was partially movable and the patient felt the pain during palpation.
  • Computed tomography (CT) showed an inhomogeneous expansive mass in the rectovaginal septum measuring 8.7 x 6.1 cm, without any signs of rectum or bladder invasion.
  • Histology showed a neoplasm with small, round to oval cells with scarce cytoplasm.
  • The patient was treated with chemotherapy followed by whole-pelvis external beam radiation and intracavitary brachytherapy.
  • RESULTS: A residual mass measuring 3.5 x 2.5 cm was visible on a control CT scan 18 months after treatment; however, the patient was feeling well and refused surgery to remove the residual mass.
  • [MeSH-major] Rectal Neoplasms / therapy. Sarcoma, Ewing / therapy. Vaginal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400989.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ulamec M, Soldo-Belić A, Vucić M, Buljan M, Kruslin B, Tomas D: Melanoma with second myxoid stromal changes after personally applied prolonged phototherapy. Am J Dermatopathol; 2008 Apr;30(2):185-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most malignant melanomas are easily diagnosed; however, melanoma is also one of the lesions most frequently reported to mimic other tumors.
  • Multiple metastatic subcutaneous nodules were also found on the scalp and trunk.
  • Chemotherapy and immunotherapy were administered as suggested by an oncologist.
  • The patient died from distant metastases 6 months after the diagnosis.
  • Although some authors believe that myxoid changes do not seem to alter the behavior of melanoma, it remains an important differential diagnosis issue.
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Staging. Risk Assessment. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360128.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Khan Durani B, Hartschuh W: [Merkel cell carcinoma. Clinical and histological differential diagnosis, diagnostic approach and therapy]. Hautarzt; 2003 Dec;54(12):1171-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma. Clinical and histological differential diagnosis, diagnostic approach and therapy].
  • [Transliterated title] Merkel-Zell-Karzinom. Klinische und histologische Differenzialdiagnose, Diagnostik und Therapie.
  • On the trunk and the buttocks, deep clinically rather inconspicuous nodules can occur.
  • The clinical differential diagnosis of the Merkel cell carcinoma includes skin metastases, malignant lymphomas, malignant adnexal tumors and cysts when the tumor is located deep in the soft tissue (e.g. on the buttocks).
  • Histological and immunohistochemical analysis is necessary for the diagnosis.
  • The demonstration of cytokeratin 20 in the typical globular distribution pattern is of main importance in the diagnosis of Merkel cell carcinoma.
  • In distant metastases, the therapy is multimodal and palliative including surgery, radiation and chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Palliative Care. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy. Skin / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 1999 Dec;175(12):611-5 [10633788.001]
  • [Cites] Br J Dermatol. 2003 Jun;148(6):1135-40 [12828740.001]
  • [Cites] Arch Surg. 1991 Dec;126(12):1514-9 [1842182.001]
  • [Cites] Arch Otolaryngol. 1984 Nov;110(11):707-12 [6487123.001]
  • [Cites] Clin Nucl Med. 2002 Dec;27(12 ):922-3 [12607889.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):228-31 [11175640.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):226-34 [9042291.001]
  • [Cites] J Cutan Pathol. 2000 Mar;27(3):118-20 [10728812.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1247-8 [9786759.001]
  • [Cites] Cancer. 1978 Nov;42(5):2311-21 [719609.001]
  • [Cites] J Dermatol Sci. 2003 May;31(3):219-24 [12727026.001]
  • [Cites] Am J Dermatopathol. 2000 Feb;22(1):65-9 [10698220.001]
  • [Cites] Lab Invest. 1985 Apr;52(4):334-53 [2580118.001]
  • [Cites] J Invest Dermatol. 1973 Jan;60(1):2-15 [4346159.001]
  • [Cites] J Am Acad Dermatol. 1999 Aug;41(2 Pt 2):289-91 [10426911.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1358-62 [11283937.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] J Am Acad Dermatol. 2002 Dec;47(6):885-92 [12451374.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8 [10067813.001]
  • [Cites] Cancer. 1980 Oct 15;46(8):1810-6 [7427884.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Ultrastruct Pathol. 1986;10(6):473-95 [2435039.001]
  • [Cites] J Nucl Med. 2001 Jul;42(7):1053-6 [11438627.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):204-8 [11314935.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):782-6 [8318209.001]
  • [Cites] Ann Oncol. 2001 Jun;12 (6):807-11 [11484956.001]
  • (PMID = 14634746.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, Taylor S, Château MC, Marquès B, Picot V, Guillou L: Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol; 2002 May;26(5):601-16
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor locations included lower extremity (36.5%), especially the thigh (28.5%), limb girdles (17.5%), upper extremity (16%), thoracoabdominal wall (9.5%), and internal trunk (20.5%).
  • Histologically, lesions show a varying combination of lipogenic and nonlipogenic areas characterized by malignant fibrous histiocytoma-like, round cell liposarcoma-like, and/or epithelioid/carcinoma-like features.
  • Treatment procedures in 51 patients consisted of simple tumorectomy (16) and wide excision (33).
  • Five and 31 patients received neoadjuvant and adjuvant chemotherapy and/or radiation therapy, respectively.
  • Seventeen patients (35%) died of disease, of whom none was metastatic at diagnosis.
  • In conclusion, pleomorphic liposarcoma is a rare, often deep-seated and limb-based aggressive and metastasizing neoplasm of late adulthood.
  • [MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11979090.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down






Advertisement